tetano
Editor, Senior Moderator
J Thromb Haemost
. 2021 Apr 8.
doi: 10.1111/jth.15339. Online ahead of print.
Placental growth factor level in plasma predicts COVID-19 severity and in-hospital mortality
David M Smadja[SUP] 1 2 [/SUP], Aur?lien Philippe[SUP] 1 2 [/SUP], Olivier Bory[SUP] 3 [/SUP], Nicolas Gendron[SUP] 1 2 [/SUP], Agathe Beauvais[SUP] 3 [/SUP], Maxime Gruest[SUP] 1 2 [/SUP], Nicolas Peron[SUP] 4 [/SUP], Lina Khider[SUP] 5 [/SUP], Coralie L Guerin[SUP] 1 6 [/SUP], Guillaume Goudot[SUP] 5 [/SUP], Fran?oise Levavasseur[SUP] 7 2 [/SUP], J?rome Duchemin[SUP] 7 2 [/SUP], Fr?d?ric Pene[SUP] 8 [/SUP], Cherifa Cheurfa[SUP] 9 [/SUP], Tali-Anne Szwebel[SUP] 8 [/SUP], Elise Sourdeau[SUP] 10 [/SUP], Benjamin Planquette[SUP] 1 11 2 [/SUP], Caroline Hauw-Berlemont[SUP] 4 [/SUP], Bertrand Hermann[SUP] 4 [/SUP], Pascale Gaussem[SUP] 1 [/SUP], Charles-Marc Samama[SUP] 9 [/SUP], Tristan Mirault[SUP] 12 13 [/SUP], Benjamin Terrier[SUP] 12 14 [/SUP], Olivier Sanchez[SUP] 10 [/SUP], Bastien Rance[SUP] 15 [/SUP], Michaela Fontenay[SUP] 7 2 [/SUP], Jean-Luc Diehl[SUP] 1 16 [/SUP], Richard Chocron[SUP] 12 17 [/SUP]
Affiliations
Abstract
Background: Coronavirus disease 2019 (COVID-19) is a respiratory disease associated with vascular inflammation and endothelial injury.
Objectives: Correlate circulating angiogenic markers VEGF-A, PlGF and FGF-2 to in-hospital mortality in COVID-19 adult patients.
Methods: Consecutive ambulatory and hospitalized patients with COVID-19 infection were enrolled. VEGF-A, PlGF and FGF-2 were measured in each patient ?48 h following admission.
Results: Study enrolled 237 patients with suspected COVID-19: 208 patients had a positive diagnostic for COVID-19 of whom 23 were mild outpatients and 185 patients hospitalized after admission. Levels of VEGF-A, PlGF and FGF-2 significantly increase with the severity of the disease (p<0.001). Using a logistic regression model we found a significant association between the increase of FGF-2 or PlGF and mortality (OR 1.11, 95% CI [1.07-1.16], p<0.001 for FGF-2 and OR 1.07 95% CI [1.04-1.10], p<0.001 for PlGF) while no association were found for VEGF-A levels. ROC curve analysis was performed and we identified PlGF above 30 pg/mL as the best predictor of in-hospital mortality in COVID-19 patients. Survival analysis for PlGF confirmed its interest for in-hospital mortality prediction, by using a Kaplan-Meier survival curves (p=0.001) and a Cox proportional hazard model adjusted to age, body mass index, D-dimer and CRP (3.23 95% CI [1.29-8.11], p=0.001).
Conclusion: Angiogenic factor PlGF is a relevant predictive factor for in-hospital mortality in COVID-19 patients. More than a biomarker, we hypothesize that PlGF blocking strategies could be a new interesting therapeutic approach in COVID-19.
Keywords: Angiogenesis; COVID-19; FGF-2; PlGF; Placental growth factor; VEGF-A; mortality.
. 2021 Apr 8.
doi: 10.1111/jth.15339. Online ahead of print.
Placental growth factor level in plasma predicts COVID-19 severity and in-hospital mortality
David M Smadja[SUP] 1 2 [/SUP], Aur?lien Philippe[SUP] 1 2 [/SUP], Olivier Bory[SUP] 3 [/SUP], Nicolas Gendron[SUP] 1 2 [/SUP], Agathe Beauvais[SUP] 3 [/SUP], Maxime Gruest[SUP] 1 2 [/SUP], Nicolas Peron[SUP] 4 [/SUP], Lina Khider[SUP] 5 [/SUP], Coralie L Guerin[SUP] 1 6 [/SUP], Guillaume Goudot[SUP] 5 [/SUP], Fran?oise Levavasseur[SUP] 7 2 [/SUP], J?rome Duchemin[SUP] 7 2 [/SUP], Fr?d?ric Pene[SUP] 8 [/SUP], Cherifa Cheurfa[SUP] 9 [/SUP], Tali-Anne Szwebel[SUP] 8 [/SUP], Elise Sourdeau[SUP] 10 [/SUP], Benjamin Planquette[SUP] 1 11 2 [/SUP], Caroline Hauw-Berlemont[SUP] 4 [/SUP], Bertrand Hermann[SUP] 4 [/SUP], Pascale Gaussem[SUP] 1 [/SUP], Charles-Marc Samama[SUP] 9 [/SUP], Tristan Mirault[SUP] 12 13 [/SUP], Benjamin Terrier[SUP] 12 14 [/SUP], Olivier Sanchez[SUP] 10 [/SUP], Bastien Rance[SUP] 15 [/SUP], Michaela Fontenay[SUP] 7 2 [/SUP], Jean-Luc Diehl[SUP] 1 16 [/SUP], Richard Chocron[SUP] 12 17 [/SUP]
Affiliations
- PMID: 33830623
- DOI: 10.1111/jth.15339
Abstract
Background: Coronavirus disease 2019 (COVID-19) is a respiratory disease associated with vascular inflammation and endothelial injury.
Objectives: Correlate circulating angiogenic markers VEGF-A, PlGF and FGF-2 to in-hospital mortality in COVID-19 adult patients.
Methods: Consecutive ambulatory and hospitalized patients with COVID-19 infection were enrolled. VEGF-A, PlGF and FGF-2 were measured in each patient ?48 h following admission.
Results: Study enrolled 237 patients with suspected COVID-19: 208 patients had a positive diagnostic for COVID-19 of whom 23 were mild outpatients and 185 patients hospitalized after admission. Levels of VEGF-A, PlGF and FGF-2 significantly increase with the severity of the disease (p<0.001). Using a logistic regression model we found a significant association between the increase of FGF-2 or PlGF and mortality (OR 1.11, 95% CI [1.07-1.16], p<0.001 for FGF-2 and OR 1.07 95% CI [1.04-1.10], p<0.001 for PlGF) while no association were found for VEGF-A levels. ROC curve analysis was performed and we identified PlGF above 30 pg/mL as the best predictor of in-hospital mortality in COVID-19 patients. Survival analysis for PlGF confirmed its interest for in-hospital mortality prediction, by using a Kaplan-Meier survival curves (p=0.001) and a Cox proportional hazard model adjusted to age, body mass index, D-dimer and CRP (3.23 95% CI [1.29-8.11], p=0.001).
Conclusion: Angiogenic factor PlGF is a relevant predictive factor for in-hospital mortality in COVID-19 patients. More than a biomarker, we hypothesize that PlGF blocking strategies could be a new interesting therapeutic approach in COVID-19.
Keywords: Angiogenesis; COVID-19; FGF-2; PlGF; Placental growth factor; VEGF-A; mortality.